The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. by Hammond, Matthew et al.
STUDY PROTOCOL Open Access
The Efficacy and Mechanism Evaluation
of Treating Idiopathic Pulmonary fibrosis
with the Addition of Co-trimoxazole
(EME-TIPAC): study protocol for a
randomised controlled trial
Matthew Hammond1* , Allan B. Clark1, Anthony P. Cahn2, Edwin R. Chilvers3, William Duncan Fraser4,
David M. Livermore4, Toby M. Maher5, Helen Parfrey6, Ann Marie Swart1, Susan Stirling1, David Thickett7,
Moira Whyte8 and Andrew Wilson4
Abstract
Background: We hypothesise, based upon the findings from our previous trial, that the addition of co-trimoxazole
to standard therapy is beneficial to patients with moderate to severe idiopathic pulmonary fibrosis (IPF). We aim to
investigate this by assessing unplanned hospitalisation-free survival (defined as time from randomisation to first
non-elective hospitalisation, lung transplant or death) and to determine whether any effect relates to changes in
infection and/or markers of disease control and neutrophil activity.
Methods/design: The EME-TIPAC trial is a double-blind, placebo-controlled, randomised, multicentre clinical trial.
A total of 330 symptomatic patients, aged 40 years old or older, with IPF diagnosed by a multidisciplinary team
(MDT) according to international guidelines and a FVC ≤ 75% predicted will be enrolled. Patients are randomised
equally to receive either two tablets of co-trimoxazole 480 mg or two placebo tablets twice daily over a median
treatment period of 27 (range 12–42) months. All patients receive folic acid 5 mg daily whilst on the trial IMP to
reduce the risk of bone marrow depression.
The primary outcome for the trial is a composite endpoint consisting of the time to death, transplant or first non-
elective hospital admission and will be determined from adverse event reporting, hospital databases and the Office
of National Statistics with active tracing of patients missing appointments. Secondary outcomes include the individual
components of the primary outcome, (1) King’s Brief Interstitial Lung Disease Questionnaire, (2) MRC Dyspnoea Score,
(3) EQ5D, (4) spirometry, (5) total lung-diffusing capacity and (6) routine sputum microbiology. Blood will be taken for
cell count, biochemistry and analysis of biomarkers including C-reactive protein and markers of disease.
The trial will last for 4 years. Recruitment will take place in a network of approximately 40 sites throughout the UK
(see Table 1 for a full list of participating sites). We expect recruitment for 30 months, follow-up for 12 months
and trial analysis and reporting to take 4 months.
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Discussion: The trial is designed to test the hypothesis that treating IPF patients with co-trimoxazole will increase the
time to death (all causes), lung transplant or first non-elective hospital admission compared to standard care
(https://www.nice.org.uk/guidance/cg163), in patients with moderate to severe disease.
The mechanistic aims are to investigate the effect on lung microbiota and other measures of infection,
markers of epithelial injury and markers of neutrophil activity.
Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 17464641.
Registered on 29 January 2015.
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Background
Idiopathic pulmonary fibrosis (IPF) is a specific form of
chronic, progressive fibrosing interstitial pneumonia of
unknown cause occurring in adults. At 7.44 per 100,000
person years [1], the incidence of IPF is similar to
subarachnoid haemorrhage, ovarian cancer, leukaemia or
mesothelioma [1, 2]. Current therapies are of limited ef-
ficacy and international guidelines only give them condi-
tional support [3]. Immunosuppressive therapy is no
longer advised [4], and the initial claims of the beneficial
effects of N-acetyl cysteine [5] have not been substanti-
ated when given as monotherapy [6]. Warfarin reduced
mortality in an open-label trial but not in a placebo-
controlled trial [7]. Pirfenidone [8, 9] and nintedanib
[10, 11] reduce the rate of decline in lung function, with
suggestions of increased survival [12].
Shulgina et al. [13] investigated the role of co-trimoxa-
zole in patients with IPF (TIPAC trial). Co-trimoxazole
960 mg twice daily for 12 months was evaluated in 181
patients with idiopathic interstitial pneumonia (IIP), 166
of whom had IPF. Although there was no effect on
forced vital capacity (FVC) (primary endpoint), co-
trimoxazole was cost-effective in the intention-to-treat
(ITT) analysis from a National Health Service (NHS)
perspective in terms of incremental cost per quality-
adjusted life years (QALYs) gained. In a per-protocol
(PP) analysis, the co-trimoxazole-treated group demon-
strated significant reductions in mortality compared to
placebo (3/53 versus 14/65, odds ratio 0.21, 95% CI 0.06
to 0.78, p = 0.02), had improvements in QALYs and re-
duced the need for oxygen therapy. The findings were
similar when confined to participants with IPF and were
not influenced by baseline immunosuppressive therapy.
The results were even more striking when considering
patients with impaired lung function. Amongst patients
with an FVC ≤ 75% of predicted normal (% predicted)
there was a close to significant (p = 0.053) treatment
effect.
As the pathogenesis of IPF is unknown the potential
mechanisms of action of co-trimoxazole are uncertain.
Co-trimoxazole is a broad-spectrum antibiotic with bac-
tericidal effects against respiratory pathogens and the
role of infection in IPF is becoming more evident [14].
However, it may have non-antimicrobial effects, target-
ing cellular processes that have been implicated in the
pathogenesis of IPF. An evaluation of efficacy by a clin-
ical trial that is adequately powered to detect clinically
important differences on clinically relevant endpoints is
required before this treatment can be considered in clin-
ical practice.
The Efficacy and Mechanism Evaluation of Treating
Idiopathic Pulmonary fibrosis with the Addition of
Co-trimoxazole (EME-TIPAC) trial is designed to test
the hypothesis that treating IPF patients with co-
trimoxazole will increase the time to death (all causes),
lung transplant or first non-elective hospital admission
compared to standard care, as defined by the National
Institute for Health and Care Excellence (NICE) guide-
lines [15], in patients with moderate to severe disease
(FVC ≤ 75% predicted). Secondary objectives are to com-
pare the clinical efficacy of this intervention in terms of
respiratory-related hospital admission, death, health-
related quality of life, QALYs, cough score and quality of
life, lung function and oxygen saturations. Secondary
mechanistic aims are to investigate the effect on (1) the
lung microbiota and other measures of infection, (2)
markers of epithelial injury and (3) markers of neutro-
phil activity. An exploratory aim is to determine whether
the mechanistic properties are related to clinical efficacy.
Methods/design
The trial is a phase III, double-blind, parallel-group, 1 to
1 randomised, placebo-controlled, multicentre clinical
superiority trial of orally administered co-trimoxazole
versus placebo in patients with moderate to severe
(FVC ≤ 75% predicted) IPF, with outcomes assessed over
a median treatment period of 27 (range 12–42) months.
Participants receive co-trimoxazole or placebo until they
meet a primary endpoint event, they withdraw consent,
or the trial concludes. This trial is designed to align with
routine care as much as possible and the trial visits are
intended to coincide with routine clinical follow-up
visits. Follow-up of assessment measures will continue
for the duration of the trial for those participants
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stopping trial medication due to adverse events or pa-
tient choice. The vital status and details of admission to
hospital will be captured for all patients who have
consented to participate in the trial regardless whether
they have withdrawn from the intervention or trial
assessments.
Figure 1 provides a study flowchart of the trial design
and Fig. 2 provides the time and event schedule. The
trial protocol (v3.0, dated 16 May 2016) is based on the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) 2013 Statement for protocols
of clinical trials (see Additional file 1).
The trial is set in UK secondary-care centres that ei-
ther meet the specifications required for specialist inter-
stitial lung disease (ILD) centre status or work in
association with specialist centres. The first patient was
randomised on 15 May 2015. In total, 330 patients will
be randomised into the trial. The trial has ethical ap-
proval from Surrey Borders Research Ethics Committee
(reference 14/LO/1800) and is registered onto a clinical
trial database (International Standard Randomised
Controlled Trials Number 17464641). The Norfolk and
Norwich University Hospital NHS Foundation Trust
(NNUH) is the trial sponsor and has delegated responsi-
bility for the overall management of the trial to the chief
investigator and Norwich Clinical Trials Unit (NCTU),
including the trial design, coordination, monitoring and
analysis and reporting of results. A Trial Management
Group (TMG) has been set up to assist with developing
the design, co-ordination and strategic management of
the trial. An Independent Trial Steering Committee
(TSC) and Independent Data Monitoring Committee
(DMC) have also been set up to provide advice to the
Table 1 Participating sites
Trust name Principal investigator
Norfolk and Norwich University Hospitals
NHS Foundation Trust
Professor Andrew Wilson
Papworth Hospital NHS Foundation Trust Dr. Helen Parfrey
Royal Brompton and Harefield NHS Trust Dr. Toby Maher
Sheffield Teaching Hospitals NHS Foundation
Trust
Dr. Stephen Bianchi
University Hospital Birmingham NHS
Foundation Trust
Professor David Thickett
Heart of England NHS Foundation Trust Dr. Gareth Walters
University Hospitals of North Midlands NHS
Trust
Dr. Helen Stone
North Bristol NHS Trust Dr. Huzaifa Adamali
Cardiff and Vale University Health Board Dr. Ben Hope-Gill
The Newcastle Upon Tyne Hospitals NHS
Foundation Trust
Dr. Ian Forrest
Gateshead Health NHS Foundation Trust Dr. Robert Allcock
Salford Royal NHS Foundation Trust Dr. Ronan O’Driscoll
University Hospital of South Manchester
NHS Foundation Trust
Dr. Nazia Chaudhuri
Aintree University Hospitals NHS
Foundation Trust
Dr. Lisa Spencer
Lancashire Teaching Hospitals NHS
Foundation Trust
Dr. Yussef Haider
Aberdeen Royal Infirmary Dr. Owen Dempsey
NHS Greater Glasgow and Clyde Dr. George Chalmers
Peterborough and Stamford Hospitals
NHS Foundation Trust
Dr. Jon Naylor
Oxford University Hospital NHS
Foundation Trust
Dr. Rachel Hoyles
Imperial College Healthcare NHS Trust Dr. Robina Coker
NHS Tayside Dr. Andrew Goudie
Royal Devon and Exeter NHS
Foundation Trust
Dr. Michael Gibbons
Hull and East Yorkshire Hospitals
NHS Trust
Dr. Simon Hart
Cambridge University Hospitals Professor Edwin Chilvers
Blackpool, Fylde and Wyre Hospitals
NHS Foundation Trust
Dr. Thomas Bongers
The Shrewsbury and Telford Hospital
NHS Trust
Dr. Richard Heinink
Sherwood Forest Hospitals NHS
Foundation Trust
Dr. Khaled Amsha
St George’s University Hospitals NHS
Foundation Trust
Dr. Raminder Aul
University College London Hospitals
NHS Foundation Trust
Dr. Joanna Porter
University Hospitals of Leicester
NHS Trust
Dr. Felix Woodhead
Worcestershire Acute Hospitals
NHS Trust
Dr. Stephen O'Hickey
Western Health and Social Care Trust Dr. Martin Kelly
Table 1 Participating sites (Continued)
Trust name Principal investigator
The Royal Wolverhampton NHS Trust Dr. Ahmed Fahim
University Hospital Southampton NHS
Foundation Trust
Dr. Sophie Fletcher
University Hospitals of Morecambe Bay
NHS Foundation Trust
Dr. Timothy Gatheral
Mid Cheshire Hospitals NHS Foundation
Trust
Dr. Duncan Fullerton
Calderdale and Huddersfield NHS
Foundation Trust
Dr. Rehan Naseer
Barts Health NHS Trust Dr. Gavin Thomas
South Tyneside Foundation Trust Dr. Liz Fuller
Medway NHS Foundation Trust Dr. Kate Brignall
University Hospitals Coventry and
Warwickshire NHS Trust
Dr. David Parr
NHS Forth Valley Dr. Mark Spears
Nottingham University Hospitals NHS
Foundation Trust
Dr. Gauri Saini
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NCTU on all aspects of the trial and safeguard the inter-
ests of trial patients. Membership of the TMG, TSC and
DMC is detailed in Table 2.
The identification, screening and enrolment logs, link-
ing participant identifiable data to the pseudoanony-
mised Participant Identification Number, will be held
locally by the research sites. Trial data will be recorded,
using the Participant Identification Number, on an elec-
tronic Case Report Form (eCRF) developed using MS
Visual Basic.NET/ASP.NET 2012 and MS SQL Server.
Remote monitoring will be performed during the trial
to ensure quality and consistency of data. A data man-
agement plan has been developed; this contains further
information on data collection and cleaning, and will be
reviewed and updated during the trial.
Patient characteristics
Patients of either gender, aged 40 years or older, are be-
ing entered into the trial. Patients are considered to have
IPF following a multidisciplinary team (MDT) consensus
decision undertaken at a specialist centre (or MDT
otherwise meeting the criteria of a specialist centre)
following a review of an appropriate clinical history,
characteristic features of usual interstitial pneumonia
(UIP) on thoracic, high-resolution computed tomog-
raphy (HRCT) and/or UIP histology confirmed by
Fig. 1 Flow diagram of study design
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surgical lung biopsy according to the latest international
guidelines [6]. There is no maximum time limit between
the diagnosis of IPF and enrolment. Patients may receive
orally administered prednisolone at a dose of up to
10 mg per day (in keeping with previous studies [11]),
anti-oxidant therapy, pirfenidone, nintedanib or other li-
censed medication for IPF. If taking licensed medication
for IPF, patients should be on a stable treatment regimen
for at least 4 weeks prior to the screening visit to ensure
that baseline values are representative. Patients must
also have a Medical Research Council (MRC) Dyspnoea
Score [16] of greater than 1, with this being defined as
‘Not troubled by breathlessness except on strenuous
exercise’, at screening in order to exclude asymptomatic
patients.
Patients with a FVC of more than 75%, as predicted
based on the algorithm suggested by Crapo et al. [17]
are not recruited into the trial; this is intended to
exclude patients with mild disease and, instead, to iden-
tify patients more likely to meet the primary endpoint
(see ‘Sample size’ section). Other reasons for exclusion
include (1) a recognised significant co-existing respira-
tory disease, e.g. obstructive airways disease (defined as
forced expiratory volume in 1 s (FEV1)/FVC < 60% [18]),
(2) a significant medical, surgical or psychiatric
condition that would affect subject safety or influence
the trial outcome or (3) untreated folate or vitamin B12
deficiency, to ensure that no bone marrow or neuro-
logical adverse effects occur with folate therapy to
vitamin B12-deficient individuals. Sulphonamides are
recognised to increase the risk of haemolysis in individ-
uals with glucose-6-phosphate dehydrogenase (G6PD)
deficiency although this risk remains low [17]. The
prevalence of G6PD deficiency is higher in men of
African, Asian or Mediterranean descent and, therefore,
patients in these demographics are screened for the con-
dition and, if found to have G6PD deficiency, are
excluded from the trial. Patients with a self-reported re-
spiratory tract infection within 4 weeks of screening
(defined as two or more of cough, sputum or breathless-
ness and requiring antimicrobial therapy) are not eligible
due to the difficulty of obtaining reliable baseline lung
function. Those patients receiving a short course of anti-
biotics (for any indication) within 4 weeks of screening
or long-term prophylactic antibiotic treatment (defined
as more than 1 month of therapy) within 3 months of
screening are also ineligible as this may have an impact
on lung microbiota. A risk of sudden death in patients
treated with co-trimoxazole and angiotensin-converting
enzyme (ACE) inhibitors was identified [19] and is
Fig. 2 Time and event schedule
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thought to be due to an increase in serum potassium
due to an amiloride-like action of trimethoprim on so-
dium channels in the distal nephron [20]. For this
reason, patients with a serum potassium greater than
5.0 mmol/L are excluded and patients with a baseline
serum potassium of between 4.7 and 5.0 mmol/L, who are
66 years old or over and taking potassium-sparing di-
uretics (including ACE inhibitors or angiotensin-receptor
blockers), are required to have an extra blood test to
measure potassium 1 week after starting trial treatment.
Identification, recruitment and randomisation
The main method of patient identification is by review
of ILD MDT meeting minutes or summaries, but is also
via screening patient registries, hospital medical records
and databases of research-interested patients. Potential
recruits are being approached by local clinic teams and
provided with a patient information sheet and given at
least 24 h to read this prior to consent. Consent is taken
by appropriately-trained clinicians or delegated members
of staff. All patients are invited to provide additional
consent to provide a sample of blood for deoxyribo-
nucleic acid (DNA) analysis; however, this is optional
and patients can refuse whilst remaining eligible for the
main trial.
Following consent, patients meeting all inclusion cri-
teria and none of the exclusion criteria (after review of
their screening bloods) may be randomised without a
subsequent visit. Randomisation is performed centrally
according to a computer-generated randomisation code
with the treatment group allocation sent to research
pharmacists only. Minimisation factors are: research site
and the use of baseline licensed medication for IPF.
Interventions
Participants receive co-trimoxazole (generic) 960 mg as
two tablets of 480 mg twice a day plus folic acid 5 mg
once a day or placebo tablets (manufactured to appear
identical to co-trimoxazole 480 mg) two oral tablets
twice a day plus folic acid 5 mg once a day over a me-
dian treatment period of 27 (range 12–42) months. This
is dispensed 3-monthly for the first 6 months then
6-monthly and supplied in bottles providing 1 month’s
supply either by hospital pharmacy or via a courier.
Participants are advised to store their medication below
25 °C but there will be no temperature monitoring after
Table 2 Trial oversight committees
Name Affiliation Role and responsibilities
Trial Management Group
Professor Andrew Wilson University of East Anglia Chief investigator
Matthew Hammond Norwich Clinical Trials Unit Clinical trial manager
Dr. Allan Clark University of East Anglia Statistician
Martin Pond Norwich Clinical Trials Unit Head of data management
Dr. Tony Cahn Bedford Hospitals NHS Trust Co-investigator
Dr. Helen Parfrey Papworth Hospital NHS Foundation Trust Co-investigator
Dr. David Thickett University of Birmingham Co-investigator
Professor Moira Whyte University of Edinburgh Co-investigator
Dr. Toby Maher Royal Brompton and Harefield NHS Foundation Trust Co-investigator
Professor Bill Fraser University of East Anglia Co-investigator
Professor David Livermore University of East Anglia Co-investigator
Professor Ann Marie Swart Norwich Clinical Trials Unit Co-investigator
In addition a patient representative will be invited to attend Trial Management Group meetings
Independent Trial Steering Committee
Professor Ron du Bois Imperial College Independent chair
Dr. Nicholas Harrison University of Swansea Independent member
Professor Ann Millar University of Bristol Independent member
Dr. Sanjay Agrawal University Hospitals Leicester NHS Trust Non-independent member
In addition a patient representative will be invited to attend committee meetings
Independent Data Monitoring Committee
Dr. Nik Hirani University of Edinburgh Chair
Dr. Jack Bowden University of Bristol Statistician
Dr. Sarah Pett MRC Clinical Trials Unit, UCL Member
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dispatch to the patient. Folic acid must be taken by
participants whilst on the trial drug to reduce the risk of
bone marrow depression associated with the long-term
use of co-trimoxazole.
The trial drug may be reduced to two tablets once a
day three times a week plus 5 mg folic acid once a day
three times a week if patients develop gastrointestinal
adverse effects or rash, have grade 1 hyperkalaemia
(serum potassium > 5.0 mmol/L and < 5.5 mmol/L) or
any other adverse event that, in the opinion of the local
investigator, requires a dose reduction. In such cases, the
dosing interval is to ensure that the dosing is spread
throughout the week (e.g. Monday, Wednesday and
Friday or equivalent). Once a patient has had their dose
reduced, no re-escalation will be permitted, even if the
adverse event leading to the reduction resolves.
Compliance to trial treatment in the form of returned
tablet counts is being monitored as part of drug
accountability at each visit. Patients are permitted to re-
ceive N-acetyl cysteine and anti-oxidants, short-term
prednisolone (any dose), long-term prednisolone (up to
a dose of 10 mg per day) and licensed treatments for
IPF. All concomitant medication is being recorded at
baseline and change in concomitant medication
recorded at each visit. Patients are permitted to receive
other medications (e.g. for other conditions), but non-
permitted therapies include: amiodarone, azathioprine,
mycophenolate mofetil, cyclophosphamide, methotrexate,
D-penicillamine, colchicine, clozapine, methenamine,
dapsone, gamma-interferon, cyclosporin, mercaptopurine,
repaglinide, pyrimethamine, lamivudine, typhoid vaccin-
ation or unlicensed medication. Therapies requiring
caution or increased monitoring include: digoxin, war-
farin, phenytoin, sulphonylureas and procainamide hydro-
chloride. Increased monitoring of potassium is required
for patients commenced on medication that increases
serum potassium concentration.
Primary outcomes
The primary outcome is the time to death (all causes),
transplant or first non-elective hospital admission.
Individuals who withdraw will be censored on the date
of withdrawal.
Secondary outcomes
The individual components of the primary outcome:
time to death (all causes) or transplant and time to first
non-elective hospital admission will be analysed separ-
ately as secondary outcomes. In addition, respiratory-
related events will be analysed separately from non-re-
spiratory-related events. The following measurements
will also be undertaken at baseline, 3 and 6 months
post randomisation, then 6-monthly for the duration
of the trial plus at the end of trial/hospitalisation.
Health-related quality of life
This is being assessed in a number of ways: (1) the King’s
Brief Interstitial Lung Disease (K-BILD) health-related
quality of life questionnaire [21] which is the only vali-
dated ILD-specific instrument. This 15-question, self-
completed patient questionnaire has a mean score of 53
(standard deviation 26) units in IPF and a minimum
clinical significant difference of 8 units; (2) the MRC
Breathlessness Score [16] which is the most widely utilised
dyspnoea score for patients with ILD; (3) the EuroQol
5-dimension (EQ5D) questionnaire [22] will be used to
determine quality-adjusted life years (QALYs) but a cos-
t-utility analysis will not be undertaken. The K-BILD does
not specifically capture cough so we are assessing cough
using a Visual Analogue Scale. Overall, quality of life is be-
ing captured using a 6-point Likert global rating of con-
cept scale.
Lung function
Spirometry [23] and the total lung-diffusing capacity of
carbon monoxide (DLCO) [24] are being measured ac-
cording to current American Thoracic Society/European
Respiratory Society guidelines. FVC and DLCO are both
components of prognostic modelling algorithms [25],
are frequently utilised in clinical trials [9] and are part of
routine care.
Peripheral blood
Peripheral blood is being taken at baseline, 3, 6 and
12 months and at the end of the trial and stored for
analysis of measures of (1) infection/inflammation, in-
cluding C-reactive protein (CRP), which is an acute-
phase serum protein that is increased in concentration
in patients with inflammation and is a significant prog-
nostic indicator for survival in patients with IPF [26]; (2)
alveolar epithelial injury including surfactant protein
(SP)-D which is elevated in serum in patients with IPF
[27] and predicts mortality [28] and matrix metallopro-
teinase (MMP)-7 which is related to disease severity [29,
30] and is an independent predictor of mortality [31]
and (3) neutrophil activity, including myeloperoxidase,
which is almost exclusively expressed in neutrophils and
is a marker of their activation and degranulation.
Routine microbiology
Sputum is being obtained, where possible, and sent for
local microbiological culture and susceptibility testing;
and a nasal swab will be sent for viral culture, if clinic-
ally indicated, in all patients.
Biomarkers
Alveolar epithelial cell injury markers (SP-D, MMP-7)
will be measured as for peripheral blood samples.
Neutrophil elastase is indicative of neutrophil activation
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and is related to disease activity in IPF [32]. Neutrophil
elastase inhibitors have been shown to reduce the devel-
opment of pulmonary fibrosis in animal models [33].
Elastase activity will be measured using the EnzChek
elastase assay (Molecular Probes). Pro-collagen III N-ter-
minal peptide (PIIINP) is a collagen turnover peptide
and a surrogate marker of fibrosis. It is elevated in
patients with IPF [34] and is higher in patients with pro-
gressive and non-progressive IPF [35].
Measurements during the first non-elective admission
Patients are being asked to carry a card detailing their
involvement in the trial and their local investigator con-
tact details. This is for safety reasons and in order to
maximise ascertainment of follow-up during hospital ad-
mission. Questionnaires, blood samples and routine
microbiology are being collected in the same manner as
undertaken at the routine visits.
Safety outcomes
Blood for full and differential white cell counts, urea and
electrolyte assays and liver function assessment is being
taken at baseline, 6 weeks, 3, 6, 9 and 12 months then
6-monthly for the duration of the trial and at the end of
trial/hospitalisation. The 6-week and 9-month blood
tests may be taken in primary care, with assessment of
adverse events being captured by phone.
Adverse events
This trial complies with UK NHS Research Ethics
Service guidelines on reporting of adverse events
(National Research Ethics Service Safety and progress
reports (Clinical Trials of Investigational Medicinal
Products (CTIMPs)); http://www.hra.nhs.uk/research-co
mmunity/during-your-research-project/safety-reporting/).
As hospitalisation and death are outcome variables they
will only be regarded as serious adverse events if they
are drug related.
Sample size
With 264 patients predicted to be randomised over a
period of 30 months and an additional 12-month follow-
up after the last patient is recruited (a total of 42 months
after the first patient is enrolled, median patient trial
duration of 27 months) we expect 96 primary endpoint
events to occur uniformly over the duration of the trial.
This will have 80% power (two-sided test, significance
level of 5%) to show a change in hospitalisation-free sur-
vival from a median value of 28.8 months in the control
arm to 51.1 months in the co-trimoxazole arm (hazard
ratio of 0.56) using a log-rank test. This is based on a
sensitivity analysis of all patients from TIPAC (including
IIP and/or IPF) with reduced lung function (FVC < 75%
predicted) using an intention-to-treat analysis.
Statistical analysis
All analyses will be conducted according to a detailed stat-
istical analysis plan. Analyses will be adjusted for site and
the use of baseline, licensed medication for IPF. The ana-
lysis populations are defined as intention-to-treat (all ran-
domised individuals regardless of adherence), per-protocol
(all randomised individuals who adhere to the trial
medication to within 80% (based on pill counts)),
modified-per-protocol (all randomised individuals who
adhere to the high-dose regimen) and safety population
(all patients randomised who received at least one dose of
the trial treatment). Non-compliance will be dealt with
using a Compliance-Adjusted-Causal-Effect (CACE) ana-
lysis, using compliance data from returned medication
(pill counts).
The primary outcome will be analysed using a Cox
proportional hazards model adjusted for the variables in-
cluded in the minimisation algorithm (baseline licensed
IPF medication and site). The results will be presented
as the Kaplan-Meier estimate of the survival function for
each treatment arm separately and, if appropriate, the
median will be estimated. The treatment effect size will
be the hazard ratio and estimated with 95% confidence
intervals and p values.
At each relevant time point from 6 weeks post ran-
domisation, the K-BILD, EQ5D, LCQ, spirometry
(FVC per cent predicted, FEV per cent predicted,
FVC absolute value, FEV absolute value and FVC/
FEV ratio) and DLCO will be analysed using linear
model to compare the average values between the
treatment arms adjusted for the variables included in
the minimisation algorithm: baseline disease-
modifying therapy and site will be included as a
random effect. The effect size will be the mean differ-
ence and will be presented with 95% confidence inter-
vals and p values.
The MRC Breathlessness Score and cough score will
be analysed using a Mann-Whitney test to compare the
distribution of the score between the treatment arms. A
generalised effect size will be estimated and presented
with 95% confidence intervals and p values.
The safety analysis will be based on the pre-defined
population (as above). Summary tables will be presented
for incidence rates (number of patients with at least one
incidence) of adverse events and serious adverse events
coded according to the Medical Dictionary for Regula-
tory Activities (MedDRA). Tables of change from base-
line will be presented for the blood and other clinical
laboratory assessments.
Requests for access to trial data and stored samples
will be considered, and approved in writing where ap-
propriate, after formal application to the TMG and TSC.
Full details of the analysis will be finalised in an ana-
lysis plan before database lock.
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Mechanistic analysis
Analysis of the biomarkers from stored blood will be
performed using the same linear mixed model as for the
analysis of K-BILD. Analysis of routine microbiology and
16S ribosomal ribonucleic acid (rRNA) sequence data
will be descriptive by tabulating the different types of
microbiological cultures and their relative prevalence or
signal strength.
Dissemination
The results of the trial will be published regardless of
the direction of effect.
All patients participating in the trial will, at the end of
the trial, be provided with a letter detailing their treat-
ment allocation with a lay summary of the trial out-
comes. General practitioners of patients participating in
the trial will also be given a copy of the trial results.
Discussion
IPF is a progressive and usually fatal lung disease with a
5-year survival of 20–40% [36]. The aetiology for the
majority of patients is unclear and there are limited
treatment options. The EME-TIPAC trial should deter-
mine whether the addition of co-trimoxazole to current
standard care improves patient-relevant outcomes in
moderate and severe disease and should explore how
co-trimoxazole may be working.
There is much debate about the choice of primary
endpoint for clinical trials of IPF. Our primary outcome
of time to death (all causes), transplant or first non-
elective hospital admission is clinically important. These
endpoints have been recommended by the Pulmonary
Fibrosis Foundation for phase 3 clinical trials in IPF
[37]. Many trials use surrogate markers of disease pro-
gression, most commonly lung function measures such
as FVC. These have the advantage that they are inexpen-
sive and relatively easy to determine, but are not reliable,
validated or adequately robust [37]. Some researchers
have claimed that the change in FVC should be used
as an endpoint, claiming that a mortality endpoint
requires unfeasibly large studies in mild to moderate
IPF [38]. The situation is, however, different when
evaluating patients with severe disease. In a meta-
analysis of placebo data of clinical trials of IPF,
annual mortality in studies selecting mild-moderate
patients was 8%, but in trials including moderate-
severe patients it was 19% [39], in keeping with the
data from TIPAC [14] and the epidemiology of the
disease [2]. The event rate of mortality and hospitali-
sations is even higher when selecting patients with
severe disease (up to 16% in 3 months [40]). Our pri-
mary outcome also meets the European Medicine
Agency criteria for composite endpoints, as hospital-
isation is an important predictor of mortality [25]. It
can be easily and reliably assessed without patient in-
volvement and is the least likely criterion to be influ-
enced by withdrawal from the trial or unintentional
or unavoidable unblinding of patients.
We have chosen to evaluate health-related quality of
life by a number of different tools. All of the question-
naires are short and easy to complete, as we are cogni-
sant of research participant burden. We decided against
using the St. George’s Respiratory Questionnaire: al-
though this has been used in a number of clinical trials
[41], it takes nearly 10 min, and participants find diffi-
culty completing it unaided [7].
Co-trimoxazole may be exerting its effect by either
antibiotic or non-antibiotic mechanisms. Infection is
common in patients with IPF – even amongst those not
receiving immunosuppression. In a meta-analysis of pa-
tients allocated to placebo from clinical trials of patients
with IPF, reported rates of pneumonia were 37.1 per
1000 patient years in studies not permitting immuno-
suppression [39] which is even higher than in chronic
obstructive pulmonary disease [42]. More than one third
of patients with IPF are colonised with pathogenic bac-
teria [43] or Pneumocystis jirovecii [44], most of which
are susceptible to co-trimoxazole. Two independent
groups of researchers using 16S technology have shown
that a heavy bacterial load [15] and a lung microbiota
profile enriched with Streptococcus and Staphylococcus
spp. [45] predict poor outcomes in IPF. We have chosen
to monitor an antibiotic effect by capturing routine
microbiological data for all patients.
Alternatively or additionally, co-trimoxazole may also
have non-antimicrobial effects, particularly on neutro-
phil function. Sulphamethoxazole-related sulphonamides
have effects on neutrophil chemotaxis [46] and super-
oxide production [47]. Co-trimoxazole or its individual
components (trimethoprim and sulfamethoxazole) also
inhibit neutrophil post-phagocytic, myeloperoxidase-
mediated protein iodination [48] and neutrophil respira-
tory burst [49, 50]. Oxidant stress has been implicated in
alveolar epithelial injury [51], and epithelial-
mesenchymal transition [52] in IPF, and IPF patients
have increased concentrations of 8-isoprostane in ex-
haled breath condensate [53]. Moreover, neutrophils
have an important role in causing oxidant stress in IPF
[54], and neutrophilic alveolitis features frequently [55].
Furthermore, higher neutrophil counts in sputum are as-
sociated with worse lung function [56] and the percent-
age of bronchoalveolar lavage fluid (BALF) neutrophils
at diagnosis is an independent predictor of mortality
[57]. We will be assessing disease-modifying effects of
co-trimoxazole by assessing recognised prognostic bio-
markers in the serum in all patients who will also
undergo measurement of neutrophil elastase at the end
of the trial.
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It is inevitable that many participants enrolled in this
trial will be frail in view of their age and disease severity.
For this reason we decided to keep the research burden
to a minimum. The project has been designed so that
the trial visits align with routine follow-up assessments
for IPF patients, and the visit time points are sufficiently
flexible to permit this. In addition (1) we have, for two
of the visits, permitted safety blood tests to be under-
taken in primary care and (2) have allowed adverse event
assessments to be undertaken by phone.
This trial will determine whether co-trimoxazole is effica-
cious in terms of reducing mortality and or hospitalisation
and should also provide some insight into its mechanism of
action. Should it be found to have beneficial effects due to
its antibiotic activity, further studies may be undertaken
using narrower-spectrum antibiotics. Alternatively, if its ac-
tivity is due to non-antibiotic mechanisms, such as effects
on neutrophil activity in IPF, further lines of research may
be possible using drugs targeting these mechanisms but
lacking antimicrobial activity, thereby obviating the collat-
eral risks of disrupting gut flora and selecting resistance.
Protocol amendments
We modified the protocol in February 2015 as we became
aware of new data regarding the risks of hyperkalaemia
with co-trimoxazole [19]. We started to exclude partici-
pants with a serum potassium greater than 5.0 mmol/L and
increase monitoring of participants with a baseline serum
potassium of between 4.7 and 5.0 mmol/L who are 66 years
old or over and taking potassium-sparing diuretics.
We modified the protocol in May 2016 to widen recruit-
ment criteria to make the trial more generalisable, taking
in to account feedback from sites, the TMG and TSC. We
removed a requirement for participants to be diagnosed
within 2 years of entry into the trial. This exclusion criter-
ion was originally included to prevent stable patients en-
tering into the trial; however, the time of diagnosis was
sometimes difficult to determine and also patients with
stable disease are unlikely to have significantly reduced
lung function (FVC). We increased the maximum FVC
value from 70% predicted to 75% predicted as this permit-
ted increased recruitment without reducing the antici-
pated event rate. We also permitted the 6-week and
9-month visits to be undertaken via the phone with local
assessment of safety bloods in order to reduce the patient
burden and increase acceptability.
The protocol also included a bronchoscopy sub-study
at a small number of selected sites, at which bronchoal-
veolar lavage fluid would be obtained from a sub-set of
50 participants at baseline and then at 3 months post
commencement of trial treatment. However, following
recommendations by the DMC and TSC, recruitment to
the sub-study was suspended due to a lack of recruit-
ment. As a result it has not been included in this paper.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address in
a clinical trial protocol and related documents. (DOC 121 kb)
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